Simultaneous Control of PTH and Ca×P Is Sustained over Three Years of Treatment with Cinacalcet HCl
Open Access
- 1 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (9) , 1465-1476
Abstract
Background & objectives: Chronic kidney disease (CKD) is commonly complicated by secondary hyperparathyroidism (SHPT), leading to increased risk of morbidity and mortality. SHPT is a progressive disease often requiring long-term therapy to control parathyroid hormone (PTH) and mineral imbalances. Vitamin D sterols and phosphate binders, used as traditional therapies to lower PTH and phosphorus, may provide inadequate long-term control for many dialysis patients. Cinacalcet, by simultaneously lowering PTH, calcium, phosphorus, and calcium-phosphorus levels, may maintain PTH and mineral balance in these individuals. However, as with traditional therapies, long-term data are limited. Design, setting, participants, & measurement: Dialysis subjects from at least one of five lead-in studies (double-blind placebo-controlled, including one extension trial) completing up to 52 wk of either cinacalcet or placebo were eligible for this open-label extension study, including an 8-wk dose titration (initiated at 30 mg/d), followed by 24-wk maintenance and up to 132 wk of follow-up. Final efficacy analysis was at week 180. Results: Three hundred thirty-four of 589 enrolled subjects received cinacalcet from the beginning of the lead-in study. Weekly median PTH values were ≤300 pg/ml (weeks 16 through 180) and median Ca×P values were ≤55 mg2/dl2 (weeks 4 through 180). Similar results were exhibited in the 255 subjects who initially received placebo. Among the patients exposed to cinacalcet from the beginning of the lead-in study, 3% of subjects exhibited treatment-related serious adverse events. Conclusions: Cinacalcet effectively maintained PTH, Ca and P reductions in dialysis subjects for up to 180 wk.Keywords
This publication has 21 references indexed in Scilit:
- Cinacalcet HCl (Sensipar/ Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidismClinical Nephrology, 2007
- Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney diseaseNature Clinical Practice Endocrinology & Metabolism, 2007
- Cinacalcet HCl: A Novel Treatment for Secondary Hyperparathyroidism Caused by Chronic Kidney DiseaseJournal of Renal Nutrition, 2006
- Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic TherapyAmerican Journal of Kidney Diseases, 2006
- Viewpoint: How Do Calcimimetics Fit Into the Management of Parathyroid Hormone, Calcium, and Phosphate Disturbances in Dialysis Patients?Seminars in Dialysis, 2005
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns StudyKidney International, 2005
- Bone metabolism and disease in chronic kidney diseaseAmerican Journal of Kidney Diseases, 2003
- Vitamin D analogues: how do they differ and what is their clinical role?Nephrology Dialysis Transplantation, 2001
- Vintage, nutritional status, and survival in hemodialysis patientsKidney International, 2000
- Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failureKidney International, 1999